One CEO, two filings, one day: the same-day swap at Quanterix and GeneDx
Everett Cunningham left Quanterix and joined GeneDx on the same day. Two more companies named interim chiefs the same week.
- Everett Cunningham resigned as president and chief executive of Quanterix on November 18, 2026, and GeneDx Holdings appointed him as its chief executive the same day. m:…8787 m:…7082
- GeneDx's filing puts Cunningham's pay at a $750,000 base salary, a $1,050,000 sign-on bonus, and $10 million each in restricted and performance-based stock awards. Self-reported m:…7082
- ACI Worldwide also changed chief executives on November 18, with Thomas W. Warsop III resigning and Robert W. Leibrock stepping in as interim president and chief executive. m:…1741
- Lantern Pharma named David Margrave interim chief executive on November 16 after Panna Sharma resigned, and reported a third-quarter operating loss of about $5.4 million. Self-reported m:…8219
The same-day swap
Everett Cunningham resigned as president and chief executive of Quanterix on November 18, 2026, and on the same day GeneDx Holdings said it had appointed him as its chief executive. The GeneDx filing says Cunningham served as Quanterix's president, chief executive and a director from January 2026 to November 2026, so his tenure there lasted less than a year before he moved. m:…8787 m:…7082
At GeneDx, Cunningham succeeds Katherine Stueland, who will step down as chief executive and resign from the board, effective on or before December 15, 2026. The filing says Stueland will stay on as an executive adviser through January 31, 2027, and that her departure is not related to any disagreement over the company's operations, policies or practices. m:…7082
Quanterix moved the same day, appointing James Gute as interim president and chief executive, effective November 18. The filing says Gute joined Quanterix in August 2026 as chief officer, after serving as senior vice president and commercial manager at Exact Sciences from August 2024 to August 2026 and spending 18 years at GE Healthcare. Cunningham will assist with the transition through December 11, 2026, and the filing says his resignation is not related to any disagreements over operations, policies or financial disclosures. m:…8787
The pay package
The filing puts Cunningham's GeneDx pay in plain numbers. The company says his initial annual base salary is $750,000, with a sign-on cash bonus of $1,050,000. He will also receive a restricted stock unit award equal to $10.0 million of GeneDx's Class A common stock and a performance-based restricted stock unit award of the same size, and he will be eligible for a target annual cash bonus equal to 100% of his base salary beginning in fiscal year 2027. m:…7082
The interim job he left behind pays the same base figure. The Quanterix filing says Gute will receive an annualized salary of $750,000 while serving as interim president and chief executive. The match is a useful yardstick: the board priced a caretaker role at the same base salary GeneDx offered its permanent hire, with the difference sitting entirely in the equity and bonus terms. m:…8787
A wider day of churn
Cunningham was not the only chief executive to move on November 18. ACI Worldwide filed that its president and chief executive, Thomas W. Warsop III, resigned effective the same day, and that Robert W. Leibrock was appointed interim president and chief executive. The filing also names Sara Arrasmith Kuhl as chief officer, Adalio T. Sanchez as executive chairman on an interim basis, and Mary P. Harman as presiding director on an interim basis. Warsop will remain with the company through December 18, 2026, to support the transition. m:…1741
Lantern Pharma's change came a few days earlier and arrived with results attached. Panna Sharma resigned as president and chief executive and as a member of the board on November 15, 2026, and David Margrave was appointed interim chief executive effective November 16. The same filing reports a third-quarter 2026 operating loss of approximately $5.4 million, including a $2.0 million accrual for a proposed settlement of claims asserted by a former consultant. The company says its cash, cash equivalents and marketable securities were approximately $7.6 million as of September 30, 2026. m:…8219
Lantern's filing also shows a company still moving its pipeline while it searches for a permanent chief. The first clinical site for its Phase 1b/2 trial in triple negative breast cancer was engaged in November 2026, and the Taiwan Food and Drug Administration approved the amended HARMONIC trial protocol in September 2026. The company formed Open Medicine AI as a wholly-owned subsidiary in July 2026 and closed a registered direct offering and concurrent private placement on September 30, 2026, for gross proceeds of approximately $4.0 million. m:…8219
What to watch
The calendar now does the talking. Cunningham assists Quanterix through December 11, takes over at GeneDx on or before December 15, and Stueland stays as executive adviser through January 31, 2027. Warsop remains at ACI through December 18. Three companies are meanwhile run by interim chiefs, and none of the filings sets a date for a permanent appointment at Quanterix, ACI or Lantern. m:…8787 m:…7082 m:…1741
The contrast in the filings is the point. GeneDx paid a sitting chief executive's price, with $20 million in stock awards on top of salary and bonus, to hire a leader the same day he resigned elsewhere. Quanterix and ACI chose interim cover, and Lantern paired its interim appointment with a loss and a thin cash balance. Whether the interims become permanents, and whether GeneDx's bet pays, will show up in the next round of filings, not in these ones. m:…7082 m:…8787
What is still unresolved
- Who will permanently lead Quanterix, ACI Worldwide and Lantern Pharma, and when will those appointments be announced?
- What GeneDx expects Cunningham to change first, given the size of the equity package tied to his appointment?
- Whether Lantern Pharma's cash balance is enough to fund its trials while it searches for a permanent chief executive?
Provenance by Synorb. Every claim links to its source. This story was written by an agent from the Manifests listed below. Read the methodology and limitations, or send a correction.
Free to reuse, including commercially. Credit “Hanging Context, with provenance by Synorb” and link to this story. Keep the cited Manifest ids. Reuse terms v1.